KYMR Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -10.86%, SMA50 -7.08%, SMA200 34.03%). The stock’s 14-day RSI is 37.37 (weak momentum), while the ATR of 4.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.84% below its high and over 250.42% above its low. Average 10-day trading volume of 669.41 thousand shares is below the 3-month average of 944.61 thousand, indicating normal recent market interest.

Kymera Therapeutics, Inc. has 71.50 million shares outstanding. The public float is 46.96 million shares, elevated short interest at 13.70% of float. This equals 7.75 million shares. The short ratio is 12.29 days. Institutional investors hold 112.83% of the float. Insiders own 2.53%. Atlas Venture Fund X, L.P. holds 828.83 thousand shares, BAKER BROS. ADVISORS LP has 701.33 thousand shares and Booth Bruce has 685.39 thousand shares. Over the past six months, insider transactions show net selling. They sold 255.50 thousand shares across 14 transactions.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) closed at $70.56 USD, gaining $2.42 (3.55%) from the previous close of $68.14. The stock is currently mid-range between its 52-week high and low $19.45 and $103.00. With a market capitalization of about $5.57 billion, Kymera Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.22). Key stats such as the average daily volume over the past year has been around 955.71 thousand shares, volume is running light vs its 52-week average. Headquartered in Watertown, MA, Kymera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nello Mainolfi, the company employs approximately 208 people and listed since August 21, 2020. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Kymera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.99. This means the shares are trading below this model’s fair value.

Kymera Therapeutics, Inc. trades at a P/E ratio of -20.12, slightly below the S&P 500 average, with a price-to-sales ratio of 122.78 and a price-to-book ratio of 6.27 trading at moderately above to book value. The P/FCF stands at -23.33, also below market averages.

Kymera Therapeutics, Inc. generated EPS of -$3.60 over the past year. Five-year average earnings growth is -26.36%. Wall Street analysts project EPS growth of -11.16% annually over the next five years. The latest quarter delivered EPS of -$0.94. The next quarter is forecast at -$0.79. Next year's EPS is expected at -$25.73. Analyst sentiment is bullish. Analyst rating data shows there are 19 Strong Buy ratings, 18 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $138.00 to $52.00. The high target offers 102.52% upside. The low target suggests -23.69% downside. The mean target is $93.73. This offers 37.56% upside. Kymera Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 30.73%. The prior quarter beat by 14.46%. Over the last six quarters, Apple has recorded several small beats. These include -15.94% in August 07, 2024.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares are down -12.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kymera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -20.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $69.88, suggesting 2.55% upside. Our AI forecast model points to short-term weakness (-5.49% over two weeks), a medium-term fall (-19.42% over three months), and a longer-term gain (23.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kymera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.49%, with price expected at $64.40 by February 03, 2026, within a range of $56.80 to $71.83 3-Month Outlook: Projected fall of -19.42%, reaching $54.91 by April 16, 2026, with a range of $53.81 to $55.92. 1-Year Outlook: Projected gain of 23.67%, with price at $84.27 by January 15, 2027, within a range of $80.09 to $87.20.